Answers are grounded in this paper and cite their sources.
Longitudinal monitoring of CD4 cell count is important for describing post-baseline immune status among people living with HIV (PLHIV). In routine registry care, CD4 testing may occur at irregular, clinically driven intervals, and observed CD4 patterns may be related to both treatment-policy era and follow-up processes. This study aimed to describe post-baseline CD4 patterns across successive observed CD4 measurements and to identify demographic, clinical, treatment-policy, calendar-period, and care-process factors associated with post-baseline CD4 levels and CD4 change among PLHIV receiving care in Isfahan, Iran. This longitudinal cohort study used routinely collected surveillance data from 972 PLHIV registered in Isfahan, Iran. Of these, 642 patients with baseline CD4 data, at least one follow-up CD4 measurement, and complete covariates for the primary model were included in the mixed-effects analysis. Baseline CD4 was defined as the first valid recorded CD4 measurement and was included as an adjustment covariate reflecting initial immune status. The longitudinal outcome consisted of 5,850 post-baseline CD4 measurements. The primary time scale was the ordered sequence of observed post-baseline CD4 measurements rather than elapsed calendar time; therefore, slope estimates should not be interpreted as monthly or annual CD4 change. Linear mixed-effects models with random intercepts and random slopes were fitted and adjusted for demographic, clinical, ART status, Treat-for-All status, diagnosis year, and visit-frequency variables. Additional sensitivity analyses included date-linked elapsed-time models, nonlinear time specifications, exclusion of unknown Treat-for-All status, and early-monitoring analyses for visit-frequency interpretation. In the adjusted model, older age and AIDS stage at diagnosis were associated with lower post-baseline CD4 levels, whereas later diagnosis year and higher baseline CD4 category were associated with higher CD4 levels. Sexual transmission was associated with higher CD4 levels compared with injecting drug use. No statistically detectable association was observed between Treat-for-All status and CD4 change across ordered measurements after adjustment for diagnosis year (interaction β = −8.11, 95% CI: −32.18 to 15.95; p = 0.508). Regular visit intervals were associated with lower CD4 increase across ordered measurements compared with frequent visits in the primary model (interaction β = −17.01, 95% CI: −24.62 to − 9.40; p < 0.001), whereas the interaction for infrequent visits was not statistically significant. Date-linked elapsed-time sensitivity analyses supported the main Treat-for-All and diagnosis-year interpretation, while visit-frequency estimates showed some sensitivity to time-scale and early-monitoring definitions. Early-monitoring sensitivity analysis suggested that visit-frequency findings should be interpreted cautiously as markers of observed care and measurement processes. Post-baseline CD4 patterns in this registry cohort were associated with age, transmission route, clinical stage at diagnosis, baseline CD4 category, diagnosis year, and observed visit-frequency patterns. Treat-for-All status should be interpreted as a policy-era marker rather than a causal treatment exposure, because implementation overlapped with secular changes in HIV diagnosis, ART availability, registry completeness, and monitoring practices. Visit-frequency findings should also be interpreted cautiously because visit frequency was derived from observed follow-up and may reflect care engagement, clinical scheduling, disease severity, and informative observation.
No takes yet. Share an insight, caveat, or question.
Nejat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: